We have also reported the effectiveness of MET inhibition, by both a MET inhibitor, tivantinib, and a specific short hairpin RNA (shRNA) against MET, in a mouse model of human breast cancer, in delaying the onset and progression of bone metastases. The gene discussed is MET; the disease is breast carcinoma.